Molecular detection of breast cancer in peripheral blood

目前乳腺癌的分期方式是侵入性的，昂贵的，缺乏敏感性。最近的鉴定基因过度表达的乳腺癌结合分子生物学的进步，提供了动力的分子诊断检测的发展，灵敏地检测外周血中的乳腺癌。候选人威廉·E.吉兰德斯医学博士是南卡罗来纳州医科大学（MUSC）外科学助理教授，立志成为一名独立的内科科学家。他在基础科学方面有很强的背景，并在该应用中提供了初步数据，即实时RT-PCR可以灵敏地检测和定量基因表达，并且磁性细胞富集技术可用于从外周血中分离乳腺癌细胞。这两种技术的成功结合为彻底改变乳腺癌分期提供了机会。这项研究的假设是，乳腺癌患者外周血中乳腺癌细胞的实时RT-PCR检测与临床结果相关。具体目标1中的实验将建立方案并确定外周血中乳腺癌细胞实时RT-PCR检测的灵敏度。密度分离介质和磁性细胞富集技术将受到严格评估。Specific Aim 2中的一项初步临床研究将证实已确立的方案在IV期乳腺癌患者中的可行性和临床相关性。在特定目标3中提出了一项相关研究，使用来自乳腺癌微创分子分期试验（MIMS）的外周血标本。MUSC有许多资源来促进候选人的研究和职业发展。其中包括霍林斯癌症中心最先进的临床和研究设施，包括外科分子肿瘤学实验室和多学科乳腺癌诊所; NIH K30临床研究课程奖，支持MUSC的多学科临床研究培训计划;以及MIMS试验，提供临床试验管理和患者样本获取方面的候选人经验。

The current staging modalities for breast cancer are invasive, expensive, and lack sensitivity. The recent identification of genes over-expressed in breast cancer combined with advances in molecular biology provide the impetus for the development of molecular diagnostic assays to sensitively detect breast cancer in peripheral blood. The candidate, William E. Gillanders, M.D., is an Assistant Professor of Surgery at the Medical University of South Carolina (MUSC) aspiring to become an independent physician scientist. He has a strong background in basic science, and presents preliminary data in this application that real-time RT-PCR allows for the sensitive detection and quantitation of gene expression, and that magnetic cell enrichment technologies can be used to isolate breast cancer cells from peripheral blood. The successful combination of these two technologies provides the opportunity to revolutionize breast cancer staging. The hypothesis of the proposed research is that real-time RT-PCR detection of breast cancer cells in the peripheral blood of breast cancer patients is associated with clinical outcome. Experiments in Specific Aim 1 will establish the protocol and define the sensitivity of real-time RT-PCR detection of breast cancer cells in peripheral blood. Density separation media and magnetic cell enrichment technologies will be rigorously evaluated. A pilot clinical study in Specific Aim 2 will confirm the feasibility and clinical relevance of the established protocol in Stage IV breast cancer patients. A correlative study is proposed in Specific Aim 3 using peripheral blood specimens from the Minimally Invasive Molecular Staging of Breast Cancer Trial (MIMS). There are a number of resources at MUSC to facilitate the candidate's research and career development. These include state-of-the-art clinical and research facilities in the Hollings Cancer Center including the Surgical Molecular Oncology Laboratory, and the Multidisciplinary Breast Cancer Clinic; and NIH K30 Clinical Research Curriculum Award supporting a multi-disciplinary clinical research training program at MUSC; and the MIMS Trial providing the candidate experience in clinical trials management and access to patient samples.